Product-enhanced reverse transcriptase assay for replication-competent retrovirus and lentivirus detection

被引:24
作者
Sastry, L
Xu, Y
Duffy, L
Koop, S
Jasti, A
Roehl, H
Jolly, D
Cornetta, K
机构
[1] Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA
[2] Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA
[3] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA
[4] BioMedica, San Diego, CA 92121 USA
关键词
D O I
10.1089/hum.2005.16.1227
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The product-enhanced reverse transcriptase (PERT) assay has been used to detect reverse transcriptase (RT) activity associated with retroviruses. Although the PERT assay has been proposed as a method for detection of replication-competent retrovirus (RCR) and lentivirus (RCL), it has not been rigorously compared with existing methods for RCR and RCL detection. We have assessed the PERT assay for detection of RCL and RCR that may contaminate lentiviral and retroviral vectors and compared it with published methods for RCL (p24(gag) ELISA/(gag) PCR) and RCR (S+/L-) detection. Our results suggest that the PERT assay is as sensitive as p24gag ELISA and gag PCR for detection of replication-competent HIV-1 in an RCL detection assay. Comparison of detection of replication-competent retroviruses, GALV and RD114, by extended S+/L- and PERT assays indicates that both assays can detect 1 IU of each virus. Our findings suggest that the PERT assay can be used for RCL and RCR testing of a variety of retroviral vectors regardless of the structure, sequence, and envelope of the vectors.
引用
收藏
页码:1227 / 1236
页数:10
相关论文
共 41 条
[1]  
Anderson WF, 1998, NATURE, V392, P25
[2]   One-step fluorescent probe product-enhanced reverse transcriptase assay [J].
Arnold, BA ;
Hepler, RW ;
Keller, PM .
BIOTECHNIQUES, 1998, 25 (01) :98-+
[3]   ACTIVE NUCLEAR IMPORT OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PREINTEGRATION COMPLEXES [J].
BUKRINSKY, MI ;
SHAROVA, N ;
DEMPSEY, MP ;
STANWICK, TL ;
BUKRINSKAYA, AG ;
HAGGERTY, S ;
STEVENSON, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (14) :6580-6584
[4]   Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system [J].
Chang, LJ ;
Urlacher, V ;
Iwakuma, T ;
Cui, Y ;
Zucali, J .
GENE THERAPY, 1999, 6 (05) :715-728
[5]   Safety testing for replication-competent retrovirus associated with gibbon ape leukemia virus-pseudotyped retroviral vectors [J].
Chen, J ;
Reeves, L ;
Cornetta, K .
HUMAN GENE THERAPY, 2001, 12 (01) :61-70
[6]   SAFETY ASPECTS OF GENE-THERAPY [J].
CORNETTA, K .
BRITISH JOURNAL OF HAEMATOLOGY, 1992, 80 (04) :421-426
[7]   INFECTION OF HUMAN-CELLS WITH MURINE AMPHOTROPIC REPLICATION-COMPETENT RETROVIRUSES [J].
CORNETTA, K ;
NGUYEN, N ;
MORGAN, RA ;
MUENCHAU, DD ;
HARTLEY, JW ;
BLAESE, RM ;
ANDERSON, WF .
HUMAN GENE THERAPY, 1993, 4 (05) :579-588
[8]  
Delenda C, 2002, CURR TOP MICROBIOL, V261, P123
[9]   HELPER VIRUS-INDUCED T-CELL LYMPHOMA IN NONHUMAN-PRIMATES AFTER RETROVIRAL MEDIATED GENE-TRANSFER [J].
DONAHUE, RE ;
KESSLER, SW ;
BODINE, D ;
MCDONAGH, K ;
DUNBAR, C ;
GOODMAN, S ;
AGRICOLA, B ;
BYRNE, E ;
RAFFELD, M ;
MOEN, R ;
BACHER, J ;
ZSEBO, KM ;
NIENHUIS, AW .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (04) :1125-1135
[10]  
Duffy L, 2003, PRECLINICA, VMay/June, P53